Plant Name: Ophioglossum vulgatum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CA2; CA1; CA7; CA12; CA9; CA14; | |
| NR0B1; | |
| NR3C1; | |
| HIF1A; | |
| SLC6A2; SLC6A3; SLCO1B3; SLCO1B1; | |
| PAX8; RAB9A; NPC1; LMNA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 0 group B | NR0B1 | Nuclear receptor subfamily 0 group B member 1 | P51843 | CHEMBL1795094 |
| Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| SLC superfamily of solute carriers | SLC6A3 | Dopamine transporter | Q01959 | CHEMBL238 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | PAX8 | Paired box protein Pax-8 | Q06710 | CHEMBL2362980 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.148E-15 | 1.121E-10 | CA1, CA12, CA14, CA2, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.112E-12 | 7.743E-08 | CA1, CA12, CA14, CA2, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.333E-10 | 1.887E-06 | CA1, CA12, CA2, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.559E-08 | 7.960E-05 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.802E-07 | 4.429E-04 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0051179; localization | GO:0015850; organic hydroxy compound transport | 2.954E-07 | 4.429E-04 | NPC1, SLC6A2, SLC6A3, SLCO1B1, SLCO1B3 |
| MF | GO:0005488; binding | GO:0046914; transition metal ion binding | 1.236E-06 | 1.495E-03 | CA1, CA12, CA2, CA7, CA9, CYP2C19, CYP2C9, CYP3A4, NR3C1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.712E-06 | 4.042E-03 | CA2, CA7 |
| MF | GO:0005215; transporter activity | GO:0005330; dopamine:sodium symporter activity | 3.712E-06 | 4.042E-03 | SLC6A2, SLC6A3 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 7.238E-06 | 6.254E-03 | CYP2C19, CYP2C9, CYP3A4, NPC1, NR0B1 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.420E-06 | 6.254E-03 | CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 7.500E-06 | 6.254E-03 | CYP2C19, CYP2C9, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.032E-14 | 4.127E-13 | CA12; CA1; CA2; CA7; CA9; CA14 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.016E-06 | 2.032E-05 | SLCO1B1; CA2; SLCO1B3; CYP3A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.143E-06 | 5.525E-05 | CYP2C9; CYP3A4; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.774E-05 | 5.774E-04 | CYP2C9; CYP3A4; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 9.670E-05 | 7.736E-04 | CYP2C9; CYP3A4; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.099E-03 | 1.316E-02 | CYP2C9; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.304E-03 | 1.316E-02 | CYP2C9; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.895E-03 | 1.448E-02 | CYP2C9; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.673E-03 | 2.966E-02 | CYP2C9; CYP2C19 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | NR3C1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | SLC6A2 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| NA: NA | Non-infectious rhinitis | NA | NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | SLC6A2; SLC6A2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | SLC6A2; SLC6A2; SLC6A2; SLC6A2; NR3C1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | NR3C1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | NR3C1 |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | NR3C1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9; HIF1A; NR3C1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | NR3C1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | NR3C1 |
| NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | NR3C1; NR3C1; NR3C1; NR3C1 |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | SLC6A2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | SLC6A2 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; HIF1A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | SLC6A2; CYP3A4; NR3C1 |
| H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | NR3C1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | SLC6A2 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | NR3C1 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | NR3C1; NR3C1; NR3C1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1 |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NR3C1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |